Page 880«..1020..879880881882..890900..»

MORRIS: The radio show in my mind | Opinion | newsbug.info – Newsbug.info

Posted: October 7, 2020 at 5:55 am

The president of the United States the leader of the free world, arguably the most powerful person on the planet has contracted a dangerous virus, and Im not sure how I should act.

Oh, I know very well what Im supposed to do. I must choose a side and root for my team from the sidelines. But how boisterous or subdued should I be, how enthusiastic or fretful?

The problem, I realize, is that Im missing the prompting Ive gotten used to. I need a cheerleader to give me the proper cues.

Like the ones I got when I briefly revisited the world of televised professional sports, after symbolically boycotting them for the intrusion of politics then actually missing them a little when they were adjourned sine die by the Trump-thumping virus.

Instead of making me endure the empty stadiums and eerie silence, the game enablers provided me with cardboard cutouts of fans in the stands and played recorded crowd noises. It helped me pretend I was watching something important that other people cared about rather than wasting my precious time on a frivolous, meaningless expenditure of testosterone.

And then there is the canned laughter that has been so instrumental in my enjoyment of situation comedies. I have never had to risk being wrong when I decided something was funny enough to be amusing. The chuckle machine showed me the way.

I notice the same laugh track has made an appearance at the return of Wheel of Fortune and Jeopardy! from their COVID-19 hiatus. I do not think an audience is there, since there are no longer panned shots people applauding. But it sure sounds present and accounted for, snickering or guffawing at the hosts witticisms.

The people who are not there. Like the sounds that really arent there in the movies I watch on Netflix that I once would have left the house for. The click of high heels on linoleum. The whoosh of wind in the trees. The crackle of flames in the fireplace.

Theyre called Foley effects, invented for radio dramas to tickle the imagination. Sound-effects specialists would make bone-injury noises with frozen romaine lettuce, horse-hoof sounds with coconut shells, thunder with thin metal sheets, creaking doors with, well, creaking doors. When sound movies came along, so did the Foley artists to add depth and immediacy to the audio quality.

Reality enhanced. Reality augmented. Reality intensified. We could use that right now.

Donald Trump is, after all, the former reality show star, the first game show host ever elected to the highest office in the land. If were all just trapped inside the ultimate reality show, shouldnt we demand the ultimate thrill ride until the next commercial break?

Trumps opponents shouldnt have to settle for merely listening to the talking heads at CNN and MSNBC excoriating the president as a fool and a knave and a heartless, incompetent dictator who should just die as soon as possible, drooling and babbling in a virus-induced fever. There should be angry mob noises at the mere sound of his name, shouts and jeers and taunts and the Foley-created sounds of torches being lit and chains being rattled.

And his supporters shouldnt be content with just watching Fox News or listening to Rush Limbaugh to hear that Trump is the best president ever, achieving historic, world-shaking successes despite the obstructionist tactics of his evil, unpatriotic opponents who are little better than treasonous scum. There should be the sounds of champagne corks popping and the majestic strains of Hail to the Chief as the adoring multitudes prayerfully chant his name.

In the radio show of my mind, I can hear the teeth gnashing, see the hair pulling, feel the cynicism building to a boiling point. Just pick a side, my fans are shouting; tell us who you think is right and wrong. Youre not fooling anyone, my critics are sneering; we know which side youre really on when youre not pretending otherwise.

But, gentle readers, during such a grave moment, a potential turning point in our history, shouldnt we be able to bridge the partisan divide and unite to work together as one great American people on a common purpose with courage and understanding?

Cue wild applause, whistles, stomping of feet, heartfelt laughter and tears of joy, shouts of Way to go, champ! and Atta Boy, Leo as America the Beautiful begins to play.

Leo Morris, columnist for The Indiana Policy Review, is winner of the Hoosier Press Associations award for Best Editorial Writer.

Read more here:
MORRIS: The radio show in my mind | Opinion | newsbug.info - Newsbug.info

Posted in Testosterone Shots | Comments Off on MORRIS: The radio show in my mind | Opinion | newsbug.info – Newsbug.info

5 things we learned from Game 2 of 2020 Finals – NBA.com

Posted: October 7, 2020 at 5:55 am

Five things we learned from the Los Angeles Lakers 124-114 victory over the Miami Heat in Game 2 of the 2020 Finals Friday in the Orlando bubble:

* * *

It certainly was a little-brother Game 2. Thats when an outcome never is in doubt and barely even competitive, thanks to the older-brother Lakers sensing they could grab control (mostly with their offense) whenever they needed to do so.

Miami essentially was kept on a bungee cord all night. Sometimes they were way behind, sometimes they were closer. After the Lakers got out in front by eight points deep into the first quarter, the closest the Heat got that period was six. In the second, L.A.s lead grew to 13, dwindled to four, then jumpedup to 14 by halftime.

Second half, more of the same: Up by 18, never leading by less than nine in the third. Then double digits for all but 20 seconds in the fourth.

Kujos, as Michael Jordan used to say, to those viewers who stuck with it to the inevitable end.

Playing without point guard Goran Dragic (plantar fasciitis) and center Bam Adebayo (neck/shoulder strain), two of its three best players, as it did Friday, Miami was pretty much airport code -- MIA -- on its way to a2-0 hole. Not to say there isnt hope, considering that four teams in Finals history have overcome that start.

The 1969 Celtics, the 1977 Trail Blazers, the 2006 Heat and the 2016 Cavaliers each clawed back to eventually celebrate. But Bill Russell, Bill Walton and Dwayne Wade arent walking through that door, and when LeBron James does so for Game 3 on Sunday(ABC, 7:30 p.m. ET), hell be turning left for the opponents locker room.

Miami can muster as much spit n vinegar as it wants, but its words arent going to hurt and its punches arent going to land as long as the Lakers have a hand on their forehead, keeping the littler fellas at an Anthony Davis-arms length.

We're never giving up, Heat leader Jimmy Butler said. We're going to fight and we're going to ride with this thing until the wheels fall off. It's not over. We're just down 0-2, so we got to do something special. We're capable of it and I wouldn't want to be in the trenches with any other guys except for the ones that we have.

Except for maybe Russell, Walton, Wade and

A case can me made for Kentavious Caldwell-Pope, a handy Derringer of a player who always seems good for a couple of timely shots each game. Alex Caruso shines, but mostly because he continues to be grossly underestimated. Kyle Kuzma? Not yet.

Its pretty clear now that the third-best, certainly the third-most valuable and important Laker in the postseason behind James and Davis is Rajon Rondo. The 34-year-old veteran of 14 NBA seasons and deep playoff runs in his long-ago Boston incarnation has been indispensable for several reasons.

Perhaps the biggest is the trust coach Frank Vogel and teammates have in Rondo to run their attack. Against Miami, that means a creator savvy enough to see whats needed -- for instance, getting into the heart of the Heats zone defense with the ability to make plays.

A second benefit is that when Rondo has the ball in his hands, James doesnt have to. Now that hes 35, if James had to play the 39 minutes he logged in Game 2 the way he used to play five or 10 years ago, hed be tuckered out or cramped up before the buzzer. This way, Rondo gets LeBron off the ball, enabling him to conserve energy on offensive possession (and take off defensive possessions less often).

Its worth a historical note here: Rondo moved up to sixth on the all-time NBA playoffs assists list Friday and now has 1,063. He passed Larry Bird (1,062) and Steve Nash (1,061) with 10 in 26 minutes.

I didnt grow up with hoop dreams, Rondo said. The past names that I passed in the playoffs from Isiah [Thomas] to Michael [Jordan] to Kobe [Bryant] to Steve and Larry. I couldnt even dream of that opportunity. I played with a lot of great teammates that obviously made shots for me.

That brings us to a third reason Rondo has been L.A.s No. 3: Now hes making shots for his teammates. Specifically, those desirable ones from the arc.

In Rondos first 96 appearances over seven postseasons from 2008 to 2017, he shot .266 (29 of 109) on 3-pointers. In his last two playoff runs, though, he has shot .439 (25 of 57). So far in this series, he has taken nine, made four.

The Heats best player -- in Dragics and Adebayos absences, definitely --took heat on the broadcast of Game 2 from Mark Jackson for not seeking out his own shot more often. We wont nitpick with that, even though Butlers 1-of-3 shooting didnt capture the eight free throws he had shot to that point (which suggests four more shots for a 28-attempt pace for the game).

Jeff Van Gundy chimed in, too, after Butler a couple of times too often attacked the paint, got near the rim, went into the air and predictably looked for a Heat teammate on the perimeter to whom he could pass. As skilled and strong as Butler is, Van Gundy said, he first should be looking to score.

Theres a case to be made that Miami needs Butler to go off for 15-20 points in the first quarter Sunday, particularly if the cavalry doesnt arrive via his two injured cohorts. It might take pressure off other guys to know the scoring load wont fall so much to them. Maybe it would get the Lakers defense to scrambling in a way they wouldnt enjoy.

Then again, Vogel and his crew could concentrate on choking off Butler completely, daring -- who, Tyler Herro, Kendrick Nunn or Kelly Olynyk to carry the day in a must-win Finals situation?

Butler finished with 25 points, eight rebounds and 13 assists. He shot 12 free throws, twice what anyone else on the floor managed. This is throwback stuff to the criticism LeBron has taken in his career for favoring the right basketball play over scoring a boatload of points. More points for Butler would have meant fewer for teammates he wouldnt have passed to.

Besides, offense wasnt the Heats problem. And lets not forget that early Jordan scored 63 in a playoff game and lost because he didnt have much help.

I will continue to play that way because that's how we're going to win, that's how we played all year long, Butler said. Just because we're in the Finals it's not going to change.

Scoring points wasnt Miamis problem -- everyone one in their authorized bubble party would tell you 114 should have been plenty to win. But their zone defense configurations never really stymied the Lakers, who seemed almost giddy in hoisting 47 3-pointers, as long as they could exploit the Heats tactic inside as well.

And exploit they did. L.A. made 33 of 50 2-pointers, scored 56 points in the paint and turned 16 offensive rebounds into 21 second-chance points. The Lakers also outscored the Heat by 15 on 3-pointers alone, lousy percentage or not.

Why play zone when the results were so bad? Miami was thin on alternatives, with its best defender (Adebayo) out and targeted guys such as Herro and Duncan Robinson playing extra minutes.

Also, Miami coach Erik Spoelstra didnt question the strategy as much as the execution. Going zone has some natural downsides -- blocking out for rebounds gets trickier, and theres a passivity that can settle in compared to man-to-man. Still, Spoelstra expected more individually within that team framework.

Said Spoelstra: I don't think it really would have mattered man or zone, there was probably eight, 10 of those possessions where we just did not finish it with that next level of commitment. This opponent is going to require us to go there.

Enough with all the talk about who isnt available for Miami. Lets talk about someone who is: Udonis Haslem. U.D., as hes known. Or the OG, as teammates call him.

If only the veteran forward could get on the court and focus his wrath on the Lakers the way he did on the Heat huddle during a third-quarter timeout.

That was a blistering, a testosterone-fueled challenge to his teammates to play harder, get tougher and empty their tanks, Butler said later. It was not suitable for the airwaves. The Heat briefly showed some life after that.

"Maybe he should just start the game off cussing people out," Butler joked.

Better still, in a series without any real dislike or certainly rancor among the players, Haslem could sprinkle a little by knocking around James and his new Super Friend Davis. Theoretically, anyway, since at 40, Haslem played only 44 minutes all season and hasnt touched the floor in the playoffs.

No one would dare say the Heat players dont respect and heed Haslems advice. Having him in uniform -- in warm-ups, at least -- gives his voice a little extra heft, in boss Pat Rileys mind, compared to sitting in a suit in the second row.

But this series is past exhortations. Haslem could lead by example, if only for a few bumpy-bangy minutes at a time. If you dont have your Bam, you have to find someone else to lay a little wham on the too-comfortable Lakers.

* * *

Steve Aschburner has written about the NBA since 1980. You can e-mail himhere, findhis archive hereandfollow him on Twitter.

The views on this page do not necessarily reflect the views of the NBA, its clubs or Turner Broadcasting.

Read more:
5 things we learned from Game 2 of 2020 Finals - NBA.com

Posted in Testosterone Shots | Comments Off on 5 things we learned from Game 2 of 2020 Finals – NBA.com

There is Help for Patients Dealing with Sexual Side Effects After Prostate, Bladder Cancer Treatment – Curetoday.com

Posted: October 7, 2020 at 5:55 am

When John Squire was first diagnosed with bladder cancer in January 2014, he was hopeful that treatment with bacillus CalmetteGuerin (BCG) would be effective. An immunotherapy vaccine made from a bacterium similar to the one that causes tuberculosis, BCG is administered through a catheter directly into the bladder, where it comes into contact with cancer cells and prompts the immune system to attack them. The advantage of this approach is that it causes few long-term side effects.

But a year later, Squires cancer came back, and this time the tumor had penetrated the muscular wall of the bladder. This meant he would need more intensive treatment.

I knew I had to have my bladder removed, but I needed to decide what kind of system I wanted to drain urine, recalls Squire, 75, of Rockville, Maryland. My options were to have the doctors construct a new bladder, have an internal pouch or an external one. I decided on the latter approach. I thought it was the simplest way to take care of urination, with the reassurance that the surgery would get rid of the cancer for good.

Yet this surgery comes with significant consequences. Dr. Trinity Bivalacqua, director of urologic oncology at Johns Hopkins Medicine, had to remove Squires bladder, prostate and seminal vesicles. Although Bivalacqua was able to spare the neurovascular bundle, which plays a key role in supplying blood to the penis and enabling men to have an erection, the surgery nonetheless injured those nerves and the surrounding muscle. For most men, this results in difficulty having an erection, or erectile dysfunction.

Squire was no exception. He tried some of the most common interventions, such as the oral medications Viagra (sildenafil citrate) and Cialis (tadalafil) and shots administered into the penis, but the pills didnt work for him, and he didnt care for the injections. He decided not to pursue those options.

For me, a traditional sex life wasnt the be all and the end all, Squire says, and that was true for my partner, Jean Sommerfield, as well. But weve been able to find other ways to give each other physical pleasure. Importantly, Ive been cancer-free for five years. Im happy that I was given another chance at life.

While Squire has adjusted well to the changes hes faced, male and female sexual problems that arise from treatment for bladder cancer, as well as those experienced by men after prostate cancer therapy, can create lasting challenges for many survivors.

Sexual dysfunction that may be temporary can develop after chemotherapy or radiation, and nerve damage from surgery can cause long-term effects. Men treated for prostate cancer with testosterone- suppressing drugs also experience sexual dysfunction. And while the problem is treatable with a variety of strategies, it is not always reversible. Only about half of men who undergo a nerve-sparing cystectomy, or removal of the bladder, recover their natural erectile function after two years, according to Bivalacqua.

Developing self-acceptance and adopting open communication with partners and new strategies for intimacy can help survivors acclimate to these changes. Fortunately, there is a lot of support available.

According to the American Cancer Society, in the United States, about 191,930 men are likely to be diagnosed with prostate cancer in 2020, while 62,100 men may receive a diagnosis of bladder cancer. That means 254,030 men may face treatment, along with its accompanying side effects.

Cystectomy is typically performed in patients with stages 2 to 4 bladder cancer, and radical prostatectomy, meaning removal of the prostate and surrounding tissues, is performed in men with stages 2 or 3 prostate cancer.

Whether a man has his prostate removed to treat prostate cancer or his bladder and prostate taken out to treat bladder cancer, the impact is going to be very similar, explains Dr. Run Wang, a urologist with UT Physicians/ McGovern Medical School at UTHealth and The University of Texas MD Anderson Cancer Center in Houston and an expert on sexual function following cancer treatment. Even with nerve-sparing surgery, the impact on sexual function is immediate.

Depending on the mans age and erectile status before surgery, it may take between three and six months for some function to start coming back, and a year or two for a maximal recovery of erection. Even then, not all men get their sexual function back.

Wang points out that its important to resume sexual activity as early as possible following surgery. By engaging in some activity, even masturbation, blood flow to the penis is increased, helping to preserve the tissue and improving the likelihood of achieving erections, he says. To help restore function through temporary methods that allow more immediate sexual activity, he adds, between 80% and 90% of men in my practice do choose some intervention following surgery.

For most men, pills are usually the first treatment option, but often they are not enough. At that point, many men try penile injections, which they learn to administer themselves, before they want to have intercourse. One medicine or a combination of several are injected into the penis. According to Bivalacqua, if the surgery was done properly, injections should result in functional erections.

If both of these interventions fail, men may consider a penile prosthesis. This device must be surgically implanted and consists of a reservoir of saline, two cylinders and a pump. When a man presses the pump, the saline flows into the cylinders, causing an erection. This device is highly effective, working for most men who use it.

Nonetheless, most men experience some depression as they come to terms with the changes in their bodies. To avoid some of the emotional shock, men and their partners should be educated before surgery about what to expect in terms of sexual function, Wang says. For example, men should be told that their erections wont be as firm, and when they have an orgasm, they will not have ejaculate.

Surprisingly, some young men are unaware that the surgery will make them infertile, so that, too, has to be made clear. Another thing many men dont know is that they can sometimes have an orgasm without an erection, usually by masturbating. Having this information on hand and being prepared for these changes helps in the recovery process, as does therapy and sexual counseling with a trained professional.

Both men and women can get bladder cancer, although it is more common in men. In addition to the 62,100 men who will likely be diagnosed in 2020, about 19,300 women will receive this diagnosis. Regardless of gender, once the cancer invades the bladders muscular wall, surgery is usually the treatment of choice. Part of the surgery involves developing a new system for draining urine. Options include an ileal conduit, which includes an external pouch; an internal pouch called a continent cutaneous pouch; or a neobladder, constructed from part of the small intestine. There are pros and cons to each approach.

Squire opted for the ileal conduit, which involves having a stoma, or opening, created in the abdomen with an ostomy bag placed over it. He thought this approach would be the easiest to manage. The internal pouch felt complicated because I would have had to use a catheter to drain it every few hours, he says. And, I heard that there was a lot of incontinence with the neobladders. The option I chose works well, though initially my ostomy bag leaked. I quickly discovered that the problem was that I wasnt using the right kind. Once I fixed that, I havent had any problems.

Dr. Mohit Khera, a urologist at Baylor College of Medicine in Houston, notes that, for some men, having an ostomy bag can affect sexual function psychologically. They may feel disfigured, he says. For this reason, a majority prefer a neobladder, but there are potential side effects associated with this approach. Urinary tract infections are pretty common, as are stones in the bladder and scarring of the ureters going into the neobladder.

With the urinary issues addressed, both men and women have to adjust to the changes in their bodies as they consider resuming a sexual relationship with their partners. Just as men will need assistance getting an erection, women sometimes have to deal with the ramifications of having their uterus and ovaries removed. In some instances, the vaginal wall, where the bladder sits, also may need to be removed, although doctors try to avoid taking out these organs whenever possible so that intercourse will remain possible. Significant changes result from surgery, many of which have a direct impact on a womans sex life.

Not only do women experience vaginal dryness, but they also may have pain during sex, Khera says. If women have an ostomy bag, they may experience poor self- image, leading to a lack of desire. Fortunately, there are remedies to address these problems.

Jeanne Carter, head of Memorial Sloan Ketterings Female Sexual Medicine and Womens Health programs in New York, concurs, emphasizing that the first step is seeking help for sexual difficulties. A woman may come alone or with a partner, and during the initial consulta- tion, we talk about her needs and concerns in a safe, comfortable environment, Carter says.

Addressing vaginal dryness and the pain and discom- fort it causes is often the place to start. Many women dont realize that theres a difference between moistur- izers and lubricants, Carter explains. Nonhormonal moisturizers are for tissue quality and come as gels, creams or suppositories. For patients with cancer and survivors, they can be applied as often as three to five times a week for symptom relief and to maintain vaginal health. Lubricants are liquids or gels that are applied for sexual touch or vaginal insertion to decrease friction and enhance enjoyment. Both complement each other and are used for different reasons.

For women experiencing vaginal tightness another common problem that arises after surgery dilators use a simple device that can help tremendously.

We recommend dilators, cylinder devices used to stretch the vagina, Carter says. They come in different sizes and can help women learn how to relax pelvic floor muscles. A smaller dilator can help reduce pain before a vaginal exam, while a larger one works to prepare the vagina for penetration. They can go a long way in reducing discomfort and building a womans confidence about intimacy and future exams.

Coupled with these approaches, Carter also suggests that women do pelvic floor exercises, called Kegel exer- cises. They involve tightening the pelvic floor muscles for three to five seconds and then relaxing them for an equal amount of time, repeating until muscle fatigue sets in. These exercises are easy to do and can help women learn how to control these muscles.

Finally, two medications approved by the United States Food and Drug Administration are available to help women who have a decreased interest in sex. Addyi (flibanserin) is a pill that acts on brain chemistry to stimulate desire. It must be taken every day. Vyleesi (bremelanotide), an injection that is administered before intercourse, also targets the brains hormones to activate desire.

Women should be aware, however, that according to the National Womens Health Network, the clinical trials included mostly White women, and the medications were effective only for a relatively small number of women between 8% and 13% for Addyi, and 8% for Vyleesi. In addition, there are side effects associated with the drugs.

The most common with Addyi are dizziness, sleepiness, nausea, fatigue, insomnia and dry mouth, and with Vyleesi, the most common are nausea and vomiting, flushing, injection site reactions and headache.

Having a fulfilling sexual relationship involves more than addressing the changes to the body resulting from treat- ment. Both men and women need to be psychologically ready, as well, which often means coming to terms with the ordeal they have been through. Daniela Whittmann, a clinical social worker, certified sex therapist and associate professor of urology at the University of Michigan in Ann Arbor, points out in a webinar presented under the auspices of the Bladder Cancer Advocacy Network that women need to go through a period of grieving for what they have lost before they can begin to build a new kind of sexual relationship. Whittmann stresses that intimacy will be different but can be just as satisfying.

Khera agrees, adding that what he calls the four pillars of health diet, exercise, sleep and stress reduction can make a big difference. Vigorous exercise 90 minutes a week, getting seven hours of sleep each night and reducing the stress in your life can help improve an individuals desire for sex, he says. And above all, avoid smoking, which can significantly increase the risk of many kinds of cancer, including bladder cancer.

Perhaps the most important part of recovery for both men and women is communication. A couple needs to talk about what they are looking for in their sexual relationship, what new ways they can give each other pleasure and how they can continue to reinforce their emotional intimacy.

Khera adds that setting new expectations and goals is a key part of the recovery process. Having a supportive sexual partner is essential, he says. If both partners encourage each other, theres a good chance that they can find a way to be successful.

Some couples learn to redefine intimacy. John and I find deep satisfaction with emotional intimacy, traveling together, spending time together and enjoying each others company at home, says Sommerfield, 72, Squires partner of seven years. John and I have maintained a fulfilling physical sexual relationship. We continue to give one another phys- ical pleasure, just not through traditional intercourse. We know that cancer doesnt stop your life. In fact, it has made us both and our relationship stronger.

See more here:
There is Help for Patients Dealing with Sexual Side Effects After Prostate, Bladder Cancer Treatment - Curetoday.com

Posted in Testosterone Shots | Comments Off on There is Help for Patients Dealing with Sexual Side Effects After Prostate, Bladder Cancer Treatment – Curetoday.com

Culprit Mutations, Risky (Neandertal) Variants, Genomic Analysis App: COVID-19 Updates – Bio-IT World

Posted: October 7, 2020 at 5:52 am

October 2, 2020| Genetic variations not driving outcomes, bio-sensing viral translation, pursuit of a passive vaccine, an Android app that analyzes the SARS-CoV-2 genome, potential antibody cocktails, targeting the hairpin, spike protein may be superantigen, implicating MAIT cells, three mutations common to COVID cases in the U.S., naturally occurring lipid and enzyme hold promise, research using breathing human lungs cells, widespread preexisting immunity, and a Neandertal gene variant that triples the risk of severe disease. Plus, an interactive exhibition about COVID-19 and an international team of experts will study how viral diseases "spill over" from animals to humans.

Research Updates

A comprehensive search of genetic variation databases has revealed no significant differences across populations and ethnic groups in seven genes associated with viral entry of SARS-CoV-2, according to a study published in Infection, Genetics and Evolution. Researchers from Boston Childrens Hospitaland Hokkaido University(Japan) surveyed publicly available databases of genomic variants, including gnomAD, the Korean Reference Genome Database, TogoVar (a Japanese genetic variation database) and the 1000 Genomes Project. Genetic variants were found in each of the seven implicated proteins, the largest number in the ACE2 receptor on the cell surface, but very few of the variations altered the functions of the proteins. The overall variation frequency was also extremely low (less than 0.01%). Findings suggest that differences in COVID-19 morbidity and mortality are not the result of genetic variationsacross populations but more likely due to preexisting medical conditions, individual medical histories, environmental factors and healthcare disparities. DOI: 10.1016/j.meegid.2020.104507

Researchers from the University of Montpellier (France) and Princeton Universityreport in Proceedings of the National Academy of Sciencesthat air emitted during plosive speech sounds(e.g. P) forms vortical puffs that travel out approximately one meter. Speech containing a train of such puffs forms a continuous, turbulent, jet-like flow capable of transporting exhaled air and droplets out to two meters or more during 30 seconds of conversation. The information could inform public health strategies for mitigating airborne disease transmission, the authors say. DOI: 10.1073/pnas.2012156117

At Colorado State University, scientists have has shown an important mechanism in the host-attacking process of infectious viruses at the single-molecule level in living cells and have reproduced these behaviors in computational models. Their experiments and models, published in Nature Structural and Molecular Biology, reveal in unprecedented detail how viruses initiate translation of genetic material into proteins. Researchers invented a biosensor that lights up blue when viral translation is happening, and green when normal host translation is happening, allowing differentiation between normal and viral host processes in real time. The biosensor also permits the effects of different types of stress that cells undergo when being attacked by a virus to be visualized, and how, where and when normal versus viral translation increase or decrease. In cells under stress, internal ribosome entry sites (IRES) translation dominates. Although SARS-CoV-2 does not contain IRES, the biosensor is modular and can easily incorporate pieces of the virus to explore how it uniquely hijacks host replication machinery during infection. DOI: 10.1038/s41594-020-0504-7

Researchers at the German Center for Neurodegenerative Diseases(DZNE) and Charit - Universittsmedizin Berlinhave identified highly effective antibodies against SARS-CoV-2 and are now pursuing the development of a passive vaccine. Thye have also discovered that some SARS-CoV-2 antibodies bind to tissue samples from the brain, heart muscle and blood vessels, which could potentially trigger undesired side effects. Their findings are reported in Cell. The scientists isolated almost 600 different antibodies from the blood of individuals who had overcome COVID-19 and then narrowed this number down to a few that were particularly effective at binding to the virus. Next, they produced these neutralizing antibodies artificially using cell cultures. Studies in hamsters confirmed the high efficacy of the selected antibodies. Development of a passive vaccine, focused on three antibodies that look particularly promising for clinical development, is now underway via a collaboration with Germany-based global biotechnology company Miltenyi Biotec. Planning has already started for clinical trials, although none are expected to begin any earlier than the end of this year. DOI: 10.1016/j.cell.2020.09.049

A newmobile app Genopodeveloped by the Garvan Institute of Medical Research(Australia) in collaboration with the University of Peradeniya(Sri Lanka)has made it possible to analyze the genome of the SARS-CoV-2 virus on a smartphone in less than half an hour. This makes genomics more accessible to remote or under-resourced regions, as well as the hospital bedside. Until now, genomic analysis has required the processing power of high-end server computers or cloud services. The new app could execute bioinformatics workflows on nanopore sequencing datasets that are downloaded to a smartphone and combines several miniaturized versions of available bioinformatics tools that work on the processing power of a consumer Android device. Researchers tested their app on different Android devices, including models from Nokia, Huawei, LG and Sony. The app is a free, open-source application available through the Google Play store and described in Communications Biology. DOI: 10.1038/s42003-020-01270-z

As reported in Science, an international team of researchers has shown that a mix of ultrapotent antibodies from recovered COVID-19 patients can recognize and lock down the infection machinery of the pandemic coronavirus and keep it from entering cells. Each of the antibody types performs these overlapping tasks slightly differently. Low doses of these antibodies, individually or as a cocktail, were also shown to protect hamsters from infection when exposed to the coronavirus by preventing it from replicating in their lungs. The presence of the antibodies additionally seems to set off the infection-fighting actions of other immune cells that arrive to clear out the virus. Besides directly preventing interactions with the host receptor, one of two discovered antibodies prevented the virus from fusing with the host membrane on the surface of the cell. Findings could pave the way to implement antibody cocktails for prophylaxis or therapy that might have the advantage of circumventing or limiting the emergence of viral escape mutants. DOI: 10.1126/science.abe3354

Small molecules that target a structure within the RNA genome of SARS-CoV-2, interfering with viral gene expression and targeting the RNA for destruction, have been identifiedby researchers from TheScripps Research Institute and Iowa State University. The so-called frameshifting element of the RNA contains a hairpin that helps the virus translate its genes into proteins, and the team found a moleculecompound 5 (C5)which decreases the hairpin's efficiency in doing its job by about 25% in cell culture experiments. To enhance the potency of C5, they attached a molecule called a ribonuclease-targeting chimera (RIBOTAC) that recruits a human enzyme to degrade the viral RNA. In cultured cells, RIBOTAC increased the potency of C5 by about 10-fold. Study findings appear in ACS Central Science. DOI: 10.1021/acscentsci.0c00984

Researchers at the University of PittsburghSchool of Medicine and Cedars-Sinaiidentified a putative T-cell receptor binding motif in the SARS-CoV-2 spike protein that is absent from other beta-coronaviruses, the sequence and structure of which resemble a bacterial superantigenic peptide that causes toxic shock syndrome. COVID-19 patients with severe hyperinflammation exhibited a T cell receptor repertoire distinct from that of patients with mild/moderate disease, suggesting that the SARS-CoV-2 spike may act as a superantigento cause multisystem inflammatory syndrome in children and cytokine storm in adults. The study published in Proceedings of the National Acadamy of Sciences. DOI: 10.1073/pnas.2010722117

Mucosa-associated invariant T (MAIT) cells, which account for a small fraction of T cells in the blood of healthy people, are strongly activated in people with moderate to severe COVID-19 disease, according to a study by researchers at Karolinska Institute(Sweden) that published in Science Immunology. MIAT cells are primarily important for controlling bacteria but can also be recruited by the immune system to fight some viral infections. Study results indicate that the number of MAIT cells in the blood of 24 patients with moderate to severe COVID-19 disease sharply decline and the remaining cells in circulation are highly activatedsuggesting they are engaged in the immune response against SARS-CoV-2. Pro-inflammatory MAIT cells also accumulated in the airways of COVID-19 patients to a larger degree than in healthy people (14 individuals), which partly explains the reduced number of MAIT cells in their blood. In convalescent patients (45 individuals), the number of MAIT cells in the blood recovered at least partially in the weeks after disease and, among four patients who had died, the MAIT cells tended to be extremely activated with lower expression of the receptor CXCR3 than in those who survived. DOI: 10.1126/sciimmunol.abe1670

Researchers in China have identified potential therapeutic effects of the anticoagulation agent dipyridamolein the severely ill patients with COVID-19. In an analysis of a randomly collected cohort of 124 patients with COVID-19, the authors found that hypercoagulability (as indicated by elevated concentrations of D-dimers) was associated with disease severity. By virtual screening of an FDA-approved drug library, they identified dipyridamole in silico, which suppressed SARS-CoV-2 replication in vitro. The original research, available online since April, appears in a recent special issue of Acta Pharmaceutica Sinica B. DOI: 10.1016/j.apsb.2020.04.008

In the same publication, Chinese researchers also report that that crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. The structural information of SARS-CoV-2 nucleocapsid protein remains unclear. A third group of researchers separately report on a molecular docking-based webserverthey have developed, called D3Targets-2019-nCoV, for predicting drug targets and for multi-target and multi-site-based virtual screening of drugs against COVID-19. Both articles were originally published online in April. DOI: 10.1016/j.apsb.2020.04.009and DOI: 10.1016/j.apsb.2020.04.006

After analyzing protein sequences for COVID-19 samples from all over the world, researchers at the University of Missouri identified three specific mutationsD614G, P323L and C241Uco-existing in every single case in the U.S.This could suggest why the virus seems to be so infectious in the country. (Their newest unpublished research indicates that resurgent COVID-19 viruses in European countries also have all three of the identified mutations in nearly all European cases.) A UM undergraduate student and middle school student in Columbia, Missouri used their computer programming skills to identify patterns in the sequences. Antiviral drugs currently being made to treat COVID-19 are developed based off the current model for the virus, but these mutations are co-evolving and causing the virus' structure to change so that those drugs may become less effective. DOI: 10.1007/s11481-020-09954-3

Researchers at Colorado State University report that neither domestic dogs nor cats developed clinical disease after being infected with SARS-CoV-2 and that infected dogs did not shed virus, whereas infected cats shed infectious virus orally and nasally for five days after infection and could infect other cats via direct contact. Cats re-exposed to the virus mounted an effective immune response and were not re-infected, suggesting that cats may be a useful model for vaccine development. Findings appeared in Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.2013102117

By examining preexisting research for other conditions, researchers at the University of Cincinnatiand multiple institutions in Germany report in the Journal of Biological Chemistrythat they have found a potential treatmentthat could be applied to COVID-19. Its a naturally occurring lipid in the human body called sphingosine known to be important in the lipid metabolism of all cells and the local immune defense in epithelial cells. Sphingosine has been shown in past studies to prevent and eliminate bacterial infections of the respiratory tract. Here, in experiments using cultured human cells with SARS-CoV-2 particles added, scientists show it binds into the cellular lock, the receptor ACE2, for the virus to prevent infection. Sphingosine could potentially be delivered as a nasal spray to prevent or treat infections, they say. DOI: 10.1074/jbc.RA120.015249

Scientists at Boston University's National Emerging Infectious Diseases Laboratories and the Center for Regenerative Medicine joined forces to develop a research model for understanding how SARS-CoV-2 impacts the lungsby engineering living, "breathing" human lung cells from stem cells for the task. According to their new findings, published in Cell Stem Cell, the trouble starts soon after the air sacs in the lungs are infected with virus, activating one of the body's biological pathways known as NFkB. Simultaneously, the virus also suppresses the lungs' ability to call in the help of the immune system to fight off the viral invaders. When the signal for help finally goes out days later, an army of immune cells swarms into lung tissue heavily laden with infected, dead, and dying cells and with unchecked levels of inflammation triggered by the early activation of NFkB. In attempting to destroy every infected cell in their path, the incoming immune cells add more fuel to the fire and can help send the lungs and other organs into total failure. The discovery of NFkB's role in this deadly cascade makes it a promising target for new therapeuticsthat could tamp down its activity early on after COVID-19 infection. Neither remdesivir nor camostat were found to completely control the inflammation unleashed by NFkB. DOI: 10.1016/j.stem.2020.09.013

Researchers from the University of California Los Angelesand China have found that catalase, a naturally occurring enzyme, holds potential as a low-cost therapeutic drugto treat hyperinflammation that occurs due to COVID-19 and suppress the replication of coronavirus inside the body. A study detailing the research was published in Advanced Materials. Inside cells, the antioxidant enzyme kick starts the breakdown of hydrogen peroxide into water and oxygen. The team first demonstrated the enzyme's anti-inflammatory effects and its ability to regulate the production of cytokines, next showed that catalase can protect alveolar cells lining the human lungs from damage due to oxidation, and finally that catalase can repress the replication of SARSCoV2 in rhesus macaques without noticeable toxicity. DOI: 10.1002/adma.202004901

Research by infectious disease experts at the University of RochesterMedical Center suggests that past colds may provide some protection from COVID-19. In fact, immunity to COVID-19 is likely to last a long timemaybe even a lifetime. Their study, published in mBio, is the first to show that SARS-CoV-2 induces memory B cells to create antibodies to destroy the viral pathogen and remember it in the future, clearing infection before it starts. The study is also the first to report cross-reactivity of memory B cells, which could mean that anyone who has been infected by a common coronaviruswhich is nearly everyonemay have some degree of pre-existing immunityto COVID-19. Findings are based on a comparison of blood samples from 26 people who were recovering from mild to moderate COVID-19 and 21 healthy donors whose samples were collected six to 10 years ago, specifically levels of memory B cells and antibodies that target specific parts of the spike protein (S2 subunits) common to all coronaviruses. DOI: 10.1128/mBio.01991-20

The COVID-19 pandemic has created a flood of potentially substandard research amid the rush to publish, with a string of papers retracted or under a cloud and a surge in submissions to pre-print servers where fewer quality checks are made, a leading ethicist from Bond University(Australia) has warned in the Journal of Medical Ethics. As of May 7, 2020, 1,221 studies on COVID-19 were registered on the international clinical trial registry site, ClinicalTrials.gov, and as of July 31, 2020, 19 published articles and 14 preprints about COVID-19 have been retracted, withdrawn, or had serious doubts raised about the integrity of their data. Most of these papers came from Asia (57.5%), with over half coming from China (58%). The reason for known in three of the 33 cases that have come under scrutinyunverifiable data (common across publications) and undisclosed conflict of interest. The authors also offer suggestions for remedying the situation. DOI: 10.1136/medethics-2020-106494

A study by researchers at Karolinska Institute(Sweden) and Max Planck Institute for Evolutionary Anthropology(Germany) that published in Natureshows that a Neandertal gene variant triples the risk of severe COVID-19. Their large international study linked a gene cluster on chromosome 3 to a higher risk of hospitalization and respiratory failure upon infection with the SARS-CoV-2 virus. The cluster is very similar to the corresponding DNA sequences of a roughly 50,000-year-old Neandertal from Croatia. The genetic risk variant is particularly common among people in South Asia(about half of the population carry the Neandertal risk variant). In Europe, one in six people carry the risk variant, while in Africa and East Asia it is almost non-existent. DOI: 10.1038/s41586-020-2818-3

Industry Updates

In Sweden, SciLifeLab(one of the largest molecular biology research laboratories in Europe) and the Visualization Center(research and science center) are collaborating to set up an interactive exhibition about COVID-19. The project is designed to facilitate communication about complex data to the public in an attractive and educational fashion using interactive multi-touch display tables and 3D technology of Interspectral AB. The visualization combines four different types of research datasets on COVID-19: the SARS-CoV-2 virus architecture, the atomic structure of the spike protein, influenced human lungs, and global aspects of the pandemic. Press release.

Tufts Universitywill lead a $100 million, five-year program to understand and address threats posed by zoonotic viral diseases that can "spill over" from animals to humans, such as SARS-CoV-2, in an effort to reduce risk of infection, amplification, and spread, the United States Agency for International Development has announced. Strategies to Prevent Spillover (aka STOP Spillover) will involve wildlife and human disease experts from both the university and organizations across the globe. These include the Africa One Health University Network; Broad Institute of the Massachusetts Institute of Technology and Harvard University; Humanitarian OpenStreetMap Team; International Centre for Diarrhoeal Disease Research, Bangladesh; Internews; JSI Research and Training Institute, Inc.; Southeast Asia One Health University Network; Tetra Tech ARD; the University of California, Los Angeles; the University of Glasgow Institute of Biodiversity, Animal Health, and Comparative Medicine; the Global Center for Health Security at the University of Nebraska Medical Center; and the University of Washington Institute for Risk Analysis and Risk Communication. Press release.

Visit link:
Culprit Mutations, Risky (Neandertal) Variants, Genomic Analysis App: COVID-19 Updates - Bio-IT World

Posted in Colorado Stem Cells | Comments Off on Culprit Mutations, Risky (Neandertal) Variants, Genomic Analysis App: COVID-19 Updates – Bio-IT World

NMDP/Be The Match partners with M Health Fairview and Duke University cryopreservation labs to launch Be The Match BioBank – Watauga Democrat

Posted: October 7, 2020 at 5:51 am

MINNEAPOLIS, Oct. 6, 2020 /PRNewswire/ --The National Marrow Donor Program (NMDP)/Be The Match today announced a collaboration with the Minnesota health system M Health Fairview and Marcus Center for Cellular Cures (MC3)/Carolinas Cord Blood Bank at Duke University (Duke) to offer cryopreservation services to transplant centers through the Be The Match BioBank. The collaboration brings together industry-leading expertise in cryopreservation and storage of patient-directed donor blood stem cell products to improve donor availability, collection quality, and ultimately, to provide a more reliable path to transplant for patients.

Through the Be The Match BioBank, blood stem cell donors will be able to donate bone marrow or peripheral blood stem cells (PBSC) for an intended patient on a timeline that is convenient for the donor. The cells are then cryopreserved and stored for the transplant center at no cost to them and shipped to coincide with initiation of the patient's conditioning regimen and optimal treatment timeline.

"We're excited to expand our partnership with Duke University by adding the expertise of physicians and researchers at M Health Fairview University of Minnesota Medical Center to continue to overcome logistical barriers to blood and marrow transplantation that might otherwise disrupt optimal patient care. Through the flexibility offered by the Be The Match BioBank, we believe we can provide transplant centers with a well-matched, available donor more often, and allow the transplant to occur at the best time for the patient," explained Steven Devine, MD, Chief Medical Officer, NMDP/Be The Match, and Associate Scientific Director, CIBMTR (Center for International Blood and Marrow Transplant Research). "The team at the Duke University lab was instrumental in the development of the Be The Match BioBank, as well as supporting donor product cryopreservation during the COVID-19 pandemic to ensure patients can continue to receive the transplants they need."

"We are proud to extend our partnership with the NMDP/Be The Match in a new way. Be The Match BioBank is an innovative way to remove barriers that otherwise may stand in the way of a patient's transplant," said Joanne Kurtzberg, MD, who leads the Marcus Center for Cellular Cures (MC3)/Carolinas Cord Blood Bank at Duke University.

"We are thrilled to be working with the NMDP/Be The Match to offer Be The Match BioBank. Through this partnership, transplant physicians can have confidence a high-quality bone marrow or PBSC product will be available from the donor they requested in the timeframe that works best for their patient," said David McKenna, MD, who leads the Molecular and Cellular Therapeutics program at M Health Fairview.

Be The Match BioBank can be used by any transplant center in the NMDP/Be The Match Network of more than 180 transplant centers worldwide. Blood stem cell donors are informed that the transplant center is requesting cryopreservation and provide consent prior to collection. Donors can also consent to having their donated cells made available to other searching patients in the unlikely event the intended patient is unable to proceed to transplant as planned.

To learn more about Be The Match BioBank, visit Network.BeTheMatchClinical.org/BioBank.

About the National Marrow Donor Program/Be The Match The National Marrow Donor Program/Be The Match is the global leader in providing a cure to patients with life-threatening blood and marrow cancers like leukemia and lymphoma, as well as other diseases. The organization manages the world's largest registry of potential blood stem cell donors and cord blood units. The NMDP/Be The Match partners with a global network to connect patients to their donor match for a transplant, and provides education and support for patients. Through Be The Match BioTherapies, the NMDP/Be The Match partners with cell and gene therapy companies to support the development and delivery of new therapies. The organization conducts research through its research program, CIBMTR (Center for International Blood and Marrow Transplant Research), in collaboration with Medical College of Wisconsin.

About M Health Fairview M Health Fairview is the newly expanded collaboration betweenthe University of Minnesota, University of Minnesota Physicians,and Fairview Health Services. The healthcare system combines the best of academic and community medicine expanding access to world-class, breakthrough care through its 10 hospitals and 60 clinics.

See the rest here:
NMDP/Be The Match partners with M Health Fairview and Duke University cryopreservation labs to launch Be The Match BioBank - Watauga Democrat

Posted in Minnesota Stem Cells | Comments Off on NMDP/Be The Match partners with M Health Fairview and Duke University cryopreservation labs to launch Be The Match BioBank – Watauga Democrat

Berks County’s first STEM-themed attraction opens, delights visitors young and old – Reading Eagle

Posted: October 7, 2020 at 5:51 am

Children of all ages and plenty of adults, too, were simultaneously entertained and educated Saturday at the opening of the Reading Science Center, Berks County's first STEM-themed attraction.

Some attendees designed roller coasters as a lesson about how potential energy and kinetic energy work. Others yanked on ropes tied to bowling balls, a pulley system designed to demonstrate how gears help bicyclists climb hills. And more still spent time their time in the cell lab taking part in experiments such as DNA extraction.

The center features 30 interactive science exhibits, plus educational programs.

"It's for ages 2 to 102," said Reading Science Center founder and board president Jim Cinelli, stressing that the exhibits aren't just fun for children. "I love this stuff."

That being said, part of Cinelli's mission is to expose students to what are often referred to as the STEM disciplines science, technology, engineering and math with the goal of generating interest in those career fields.

"There was one study that shows STEM science centers are effective in doing that," said Cinelli. "Kids will be 30 to 40% more likely to enter a career in STEM if they get to a science center three or more times before seventh grade."

For some families, that's easier said than done.

"That's the kicker: three or more times," said Cinelli. "Your community is at a disadvantage if you don't have one locally."

Cinelli notes that many surrounding areas already have a STEM attraction, rattling off Lancaster, Harrisburg, Allentown and Philadelphia as examples.

However, there was no such place in Berks, a region with 18 school districts.

"We not only wanted it to be in Berks County," said Cinelli, "but for the really underserved population of Reading, we wanted it to be downtown so really it's accessible to everyone."

The Reading Science Center plans to host school-sponsored events and field trips, though those are on hold due to the coronavirus.

Other activities inside the 7,000-square-foot Reading Science Center located inside the multi-use building at 645 Penn St. include a structural engineering where participants can build a bridge and test its stability in an earthquake; a sand pendulum that demonstrates how gravity works; and an early learners section where young children can build on Lego tables.

The cell lab is one of the center's highlights.A donation from the Science Museum of Minnesota valued at about $500,000, it allows visitors to study their own cells under a microscope.

"I don't think you're going to find anything like this anywhere in our area," Cinelli said.

Classroom space is available for workshops, seminars and group experiments.

President of Reading-headquartered Liberty Environmental Inc., Cinelli had been pushing to get the Science Center open for more than three years, describing what he saw as an area of need for the community where he lives.

"I'm here for good," Cinelli said. "I'm born and raised in Berks, have my business here, bought a building downtown three years ago so I have a vested interest in seeing Berks County and the city of Reading thrive."

Cinelli was quick to credit the work by volunteers, some of whom were working right up to opening to ensure all the exhibits were ready.

Mary Chown, interim executive director for the Reading Science Center, assisted in securing donations from individual donors and local foundations to turn a vision into reality.

Donations can be made by visiting readingsciencecenter.org or by emailing Chown at mary.chown@rdgsci.org.

Read the original here:
Berks County's first STEM-themed attraction opens, delights visitors young and old - Reading Eagle

Posted in Minnesota Stem Cells | Comments Off on Berks County’s first STEM-themed attraction opens, delights visitors young and old – Reading Eagle

What You Need to Know About Prop 14, The Stem Cell Research Bond (Transcript) – KQED

Posted: October 5, 2020 at 2:56 pm

Olivia Allen-Price [00:01:55] OK, so what exactly does this bond fund?

Danielle Venton [00:01:59] This would fund $5.5 billion in stem cell research and treatments in California. Some of the diseases that stem cell research is seeking to cure or treat include cancer, Alzheimer's disease, diabetes, spinal cord injuries, blindness, and even COVID-19. I spoke recently with a guy named Jake Javier. He supports this bond initiative because he knows firsthand how life changing stem cell research can be.

Jake Javier [00:02:25] I am in my last year at Cal Poly.

Danielle Venton [00:02:28] So, Jake grew up locally in Danville and was just graduating high school when he suffered a life altering injury.

Jake Javier [00:02:35] On the last day of high school, I drove in to a pool and hit my head on the bottom and broke my neck and was immediately paralyzed.

Danielle Venton [00:02:47] He says his injury was complete, with very little hope of recovery. But a doctor at Stanford reached out to Jake and his family and said, you can be part of this clinical trial where we, with a one time surgery, will inject stem cells into the damaged area and you may possibly see some benefits.

Danielle Venton [00:03:07] Now, Jake is still injured.

Jake Javier [00:03:09] I'm a quadriplegic. I use a wheelchair.

Danielle Venton [00:03:11] But he says after the surgery, he noticed more movement in his arms, in his hands.

Jake Javier [00:03:17] So, I mean, with my injury, I'm at a level where I would normally not have any function at all in my hands and very, very little function like in my triceps and things like that. Muscles that are really important for functionality and, you know, being able to get through day to day activities that could help me push myself around more, help me transfer in and out of my chair independently. And then also, I notice, you know, I got some some finger movement. It doesn't seem like much, but even that little movement has helped me so much with picking things up and things like that. So it was really, I was really blessed to see that happen.

Danielle Venton [00:03:51] So he doesn't know how much of his recovery is due to the stem cells. How much is natural, or how much is due to physical therapy. But today he's able to live independently, to go to college and he wants to pursue a career in medicine. And he is a big believer in stem cell research, regenerative medicine, and is really hoping that California voters will support this proposition.

Olivia Allen-Price [00:04:20] Now, what exactly are stem cells and how do they work, I guess?

Danielle Venton [00:04:25] Yeah, stem cells are types of cells that can be turned into any type of specialized cell. Scientists have known about them since the eighteen hundreds, but it wasn't until the late 90s that researchers developed a method to derive them from human embryos and grow them in a laboratory. And then people really began to get excited about their potential for medicine. Now these cells came from unused embryos created for in vitro fertilization, and they were donated with informed consent. But many anti-abortion groups felt that using the cells were tantamount to taking a human life. So in 2001, then President George W. Bush banned federal funding for any research using newly created stem cell lines.

Olivia Allen-Price [00:05:09] OK. And how does that get us now to bonds in California?

Danielle Venton [00:05:13] Well, Californians wanted to circumvent these federal restrictions, and in 2004 voted for a bond that gave the state $3 billion to create a research agency called the California Institute of Regenerative Medicine, or CIRM. There was a lot of public support for it. And it just felt like these wonderful cures could be right around the corner. Celebrities like Michael J. Fox appeared in TV commercials.

Michael J. Fox TV commercial [00:05:36] My most important role lately is as an advocate for patients, and for finding new cures for diseases. That's why I'm asking you to vote yes on Proposition 71, Stem Cell Research Initiative.

Danielle Venton [00:05:48] And the money for that research, that $3 billion, has now run out. And to continue their work, the stem cell advocacy group, Americans for Cures, is asking voters for more money.

Olivia Allen-Price [00:06:00] So we're basically voting on whether we want to refill the stem cell research piggy bank here.

Danielle Venton [00:06:05] Yeah, exactly. Some question if the state can afford this at this time when budgets are going to be so tight. Others have been disappointed by the slow pace of cures coming out of the field. Now, there are people who credit this research, such as Jake, with improving or restoring their health or the health of their loved ones. Or maybe they hope that one day it will, and they would balk at the idea that this is not worthy research. They point to achievements that the agency has funded. That includes effectively a cure for bubble baby disease. This is when someone is born without a functioning immune system. That mutation can now be corrected with genetically modified stem cells. And recently, just within the last year or so, the FDA approved two new treatments for blood cancer, developed with CIRM support. These achievements are what the agency points to when they're criticized for not having accomplished more. And they say the process of scientific discovery is long and unpredictable.

Olivia Allen-Price [00:07:04] Now, wasn't that Bush-era ban on stem cell research that you were talking about earlier wasn't that overturned?

Danielle Venton [00:07:11] Yes, that was overturned by President Obama. However, there are current members of Congress who are lobbying President Trump to ban the research again. And if that happens, then California would be the only major player in stemcell research once again in the United States.

Olivia Allen-Price [00:07:30] All right, so who is supporting Prop 14?

Danielle Venton [00:07:32] Governor Gavin Newsom, for one. Many patient advocacy organizations and medical and research institutions, including the California Board of Regents. These people don't want to see the pace of this research slow. They want it to accelerate. The political action committee supporting this proposition is reporting more than six million dollars in contributions.

Olivia Allen-Price [00:07:53] All right. And what about the opposition? Who's against it?

Danielle Venton [00:07:55] Well, so far, there's no organized, funded opposition. There have been several newspaper editorials coming out against it, including locally, the Mercury News and the Santa Rosa Press Democrat. They basically say state bonds aren't the way to fund research and the situation isn't like it was in 2004 and that the institute should now seek other sources of funding and move forward as a nonprofit.

Olivia Allen-Price [00:08:19] All right, Danielle. Well, thanks, as always for your help.

Danielle Venton [00:08:21] My pleasure. Thanks.

Olivia Allen-Price [00:08:28] In a nutshell, a vote yes on Proposition 14 says you think Californians should give $5.5 billion to the state's stem cell research institute. That money will be raised by selling bonds, which the state would pay back, with interest, out ofthe general fund over the next 30 years. A vote no means you think we shouldn't spend public money on this research.

Olivia Allen-Price [00:08:54] That's it on Proposition 14. We'll be back tomorrow with an episode on Prop 15. And oh, it is a doozy. Commercial property tax! A partial rollback of one of California's most controversial propositions! It's going to be fire. In the meantime, you can find more of KQED election coverage at KQED.org/elections. Two reminders on the way out: October 19th is the last day to register to vote and mail in ballots must be postmarked on or before November 3rd.

Olivia Allen-Price [00:09:28] Bay Curious is made in San Francisco at member supported KQED. I'm Olivia Allen-Price. See you tomorrow.

More:
What You Need to Know About Prop 14, The Stem Cell Research Bond (Transcript) - KQED

Posted in California Stem Cells | Comments Off on What You Need to Know About Prop 14, The Stem Cell Research Bond (Transcript) – KQED

UC Davis Engineers Lead $36M Effort to Improve Recovery From Spinal Cord Injuries – UC Davis

Posted: October 5, 2020 at 2:56 pm

Engineers at the University of California, Davis, will lead a consortium of universities, biomedical startups and nonprofit organizations to develop interventions for spinal cord injuries that can be applied within days of injury to improve long-term outcomes.

Karen Moxon, professor of biomedical engineering at UC Davis, will lead the five-year, $36 million contract as part of the Defense Advanced Research Project Agency, or DARPA, Bridging the Gap Plus Program. A primary goal is to develop technologies to stabilize a patients hemodynamic response, which includes blood flow and blood pressure, within days of injury.

Because large swings in blood pressure are common following spinal cord injuries, stabilizing hemodynamics within days of injury will improve functional recovery. The team will take advantage of stabilized hemodynamics to optimize delivery of neural stem cells using personalized 3D printed scaffolds within two weeks of injury to regenerate lost connections within the injured spinal cord.

Spinal cord injury is a complex condition that causes partial or complete loss of function below the location of injury, Moxon said. We will develop systems for real-time biomarker monitoring and intervention to stabilize and rebuild neural communications pathways between the brain and spinal cord. As a result of our efforts, clinicians will be able to collect previously unavailable diagnostic information for automated or clinician-directed interventions. Our goal is to translate these technologies to humans within the five-year award period.

The international team includes 12 institutions: UC Davis, UC San Diego, UC San Francisco, the University of British Columbia, the University of Calgary and the cole Polytechnique Fdrale de Lausanne (EPFL, Switzerland); biotech startups Pathonix Innovation Inc. of Vancouver, GTX Medical (Lausanne, Switzerland), and Teliatry (Richardson, Texas); nonprofit institutions the Wyss Center for Bio and Neuroengineering (Geneva, Switzerland) and Battelle Memorial Institute (Columbus, Ohio); and a regulatory consultant firm, NetValue BioConsulting Inc., Toronto.

Moxon and her team at UC Davis including Zhaodan Kong, associate professor in the Department of Mechanical and Aerospace Engineering, and Professor Kiarash Shahlaie and Assistant Professor Julius Ebinu, neurosurgeons in the UC Davis School of Medicine will take the lead on assessing the impact of these interventions on the brain to maximize the restoration of both motor and sensory functions. This part of the project will be conducted at the California National Primate Research Center.

We are extremely pleased that the California National Primate Research Center will host the nonhuman primate research arm of this extraordinary effort to restore function following spinal cord injury, said center director John Morrison, professor of neurology at UC Davis.

Part of the effort will also aim to improve functional recovery, using neural stem cell and bioengineering scaffold technology developed by professors Mark Tuszynski, Paul Lu, Ephron Rosenzweig and Jacob Koffler, all faculty in the Department of Neurosciences at UCSD. Their stem cell and scaffold technology will be combined with neural electrical stimulation technology (neuromodulation) developed by Gregoire Courtine at EPFL. The team hopes to successfully combine this cell and engineering technology to promote nerve regeneration that bridges the injury site.

Moxons lab at UC Davis, in collaboration with a teamat the Wyss Center for Bio and Neuroengineering led by Tracy Laabs, will develop cortical stimulation protocols to enhance sensory feedback to the brain and aid in motor control. The team will take advantage of Wysss ABILITYsystem that wirelessly records signals from individual neurons in the brain and will further develop it to include closed-loop cortical stimulation, which employs a sensor to record signals, for improved motor function.

The multi-institution team will focus on advancing three main technologies:

Together, these technologies will integrate into a system-of-systems that monitors the information from sensors and stimulators to allow clinicians to monitor patients progress. At the same time, the team will be able to identify the optimal time to transplant the neural stem cells and 3D scaffold in this critical time period after injury.

It is exciting to lead this talented team of international scientists and to be in a position to effect real change for people who sustain a spinal cord injury, Moxon said. Its this type of team science between academia and industry that makes clinical breakthroughs possible in short time periods.

Development of the proposal for the award was facilitated by the UC Davis Office of Researchs Interdisciplinary Research Support team and Gabriela Lee, project manager. This project is part of a larger effort at UC Davis led by Moxon, Professor Sanjay Joshi in the Department of Mechanical and Aerospace Engineering, and Professor Carolynn Patten in the School of Medicine and College of Biological Sciences to develop a neuroengineering program that aims to restore, augment and extend human capacity to benefit society.

Here is the original post:
UC Davis Engineers Lead $36M Effort to Improve Recovery From Spinal Cord Injuries - UC Davis

Posted in California Stem Cells | Comments Off on UC Davis Engineers Lead $36M Effort to Improve Recovery From Spinal Cord Injuries – UC Davis

Dust off the crystal ball: It’s time for STAT’s 2020 Nobel Prize predictions – STAT

Posted: October 5, 2020 at 2:56 pm

The mistake Nobel Prize prognosticators yours truly included make is to look through the greatest hits of biochemistry, biology, and medicine (the areas STAT covers) nuclear hormone receptors! microRNAs! and figure (as last years prediction story did) one of those is due and deserving. The trouble is, as MITs Phillip Sharp, who shared the 1993 medicine Nobel, told me, There is just a lot of good science that will never get recognized.

So focusing on the greatest hits to forecast the science winners who will be announced next week is too simplistic. Theyre all contenders, but the smart money looks for other criteria. Like toggling between discoveries of what cells and molecules do and inventions of techniques that reveal what they do, or between disciplines, or (for medicine) between something that directly cures patients and something about the wonders of living cells.

By that criteria, it might be a techniques turn, since the last such winner in medicine was for turning adult cells into stem cells, in 2012. Could this be the year for optogenetics, which allows brain scientists to control genetically modified neurons with light? I dont think optogenetics has made a big enough impact outside of neuroscience yet, said cancer biologist Jason Sheltzer of Cold Spring Harbor Laboratory, who dabbles in Nobel predictions, but who knows.

advertisement

The last Nobel for DNA sequencing was way back in 1980, he pointed out, and since then we have seen the complete sequencing of the human genome, one of humanitys towering achievements. (Sheltzer correctly predicted 2018s medicine Nobel for immuno-oncology pioneer James Allison. The Human Genome Project could win it for the officials who led it, like Francis Collins of the National Institutes of Health and Eric Lander of the Broad Institute. Would Craig Venter, who led a competing private effort, make it to Stockholm, too? Let the betting commence!

Just to be clear, science Nobels arent chosen all that, well, scientifically. For medicine, a five-member Nobel Committee for Physiology or Medicine at Swedens Karolinska Institute sifts nominations and selects candidates. The 50-member Nobel Assembly votes, this year on Oct. 5. So you can get head-scratchers from, say, 20-18-12 or similarly split votes if, say, genetics fanciers split their votes among two contenders. (If you want to know if that happened, hang on until 2070: Nobel records are secret and sealed for 50 years.) For chemistry, chosen on Oct. 7 this year, the five-member Nobel Committee of the Royal Swedish Academy of Sciences likewise sifts nominations and recommends finalists to the academy for a vote.

advertisement

Besides invention and discovery switching off in the medicine Nobel, there certainly seems to be periodicity in terms of disciplines taking turns, said David Pendlebury of data company Clarivate Analytics. He has made 54 correct Nobel predictions (usually in the wrong year, but in 29 cases within just two) since 2002 by analyzing how often a scientists key papers are cited by peers and awarded predictive prizes like the Lasker or Gairdner awards.

Neuroscience won the medicine Nobel in 2000, 2004, 2014, and 2017, immunology in 2008, 2011, and 2018, for instance. Infectious disease and cancer win every decade or two, and so are probably also-rans for 2020. Thats why STAT said last year that the 2018 medicine award for immuno-oncology made cancer an unlikely 2019 winner. Yet William Kaelin, Peter Ratcliffe, and Gregg Semenza won for discovering how cells sense and adapt to oxygen availability, through gene regulation, which is tangentially related to cancer. Go figure.

For the medicine prize, periodicity also applies to toggling between super-basic molecular biology and stuff that actually cures people (not year by year, but generally). Last years award for how cells sense changing oxygen levels was pretty abstruse and might shape this years choice.

Prizes with a more clinical focus have been 2003 (MRI), 2005 (H. pylori and ulcers), 2008 (HIV), 2015 (roundworm and malaria therapy), and 2018 (immuno-oncology), [so] maybe a clinical type of prize this year, [such as] hepatitis C treatment, brain stimulation for Parkinsons, cochlear implant, statins Pendlebury said. We wouldnt be surprised at a hep C win for Charles Rice of Rockefeller University and Ralf Bartenschlager of Heidelberg University (2016 Lasker winners) for the super-basic discoveries that led to drugs that cure the viral disease.

Like Pendlebury, Sheltzer believes in predictive prizes. I looked back at the last 20 years of Nobel Prizes in medicine/physiology, he said. Eighty-three percent of them had won at least one of three prizes before the Nobel: the Lasker, the Gairdner, or the Horwitz Prize. Of the five people who have recently won all three, only one works in a field so far ignored by the Nobel committees, he said: Yale School of Medicines Arthur Horwich, a pioneer of protein folding and chaperone proteins. In addition to the Gairdner in 2004, Horwitz in 2008, and Lasker in 2011, he received the $3 million Breakthrough Prize in 2019. So thats guess #1, Sheltzer said.

Unless Weve had a few [medicine] awards that you could classify as cell biology recently oxygen sensing in 2019, autophagy in 2016, even immune regulation is kinda cell biological, Sheltzer acknowledged. So I think a genetics award is more likely than one to Horwich, whose discoveries about how cells fold the proteins they synthesize are central to the understanding of life. STATs nickel says look no further than the 2015 Lasker Basic Medical Research Award: It honored Evelyn Witkin of Rutgers and Stephen Elledge of Harvard for discovering how DNA repairs itself after being damaged.

Might David Allis of Rockefeller and Michael Grunstein of UCLA finally get the call to Stockholm? They discovered one way genes are activated (through proteins called histones). Theyve shared a 2018 Lasker and a 2016 Gruber Prize in Genetics, and basically launched the hot field of epigenetics. I think a prize related to epigenetic control of transcription by DNA and histone modifications could be in order, Kaelin told STAT.

For physiology or medicine, Pendlebury likes Pamela Bjorkman of Caltech and Jack Strominger of Harvard for determining the structure and function of major histocompatibility complex (MHC) proteins, a landmark discovery that has contributed to drug and vaccine development, as well as Yusuke Nakamura of the University of Tokyo for genome-wide association studies that led to personalized approaches to cancer treatment (personally, we doubt this is cancers year again), and Huda Zoghbi of Baylor College of Medicine for work on the origin of neurological disorders.

In chemistry, Pendlebury likes Moungi Bawendi of MIT, Christopher Murray of the University of Pennsylvania, and Taeghwan Hyeon of Seoul National University for synthesizing nanocrystals, a cool new way to deliver drugs, and Makoto Fujita of the University of Tokyo for discovering supramolecular chemistry, in which lab-made molecules self-assemble by emulating how nature makes them. That has some overlap with Frances Arnolds 2018 Nobel for chemistry, so were skeptical, but who knows?

Lets address the elephant in the Nobel anteroom, and the chatter that the revolutionary genome editing technique CRISPR will win for chemistry. (Its value in medicine is still TBD, but its stellar biochemistry.)

The discovery of the CRISPR-Cas9 system is certainly worthy of a Nobel Prize, Kaelin said. I suspect the challenge here will be to get the attribution right. Perhaps there could be a chemistry prize for the basic mechanism and a medicine prize for application to somatic gene editing in human cells.

By attribution, he means, who gets CRISPR credit? Only three people can share a Nobel. But CRISPR has more mothers and fathers than that. Jennifer Doudna of the University of California, Berkeley, and her collaborator Emmanuelle Charpentier have won a slew of predictive prizes for their work turning a bacterial immune system into a DNA editor, but dark horse Virginijus iknys of Vilnius University shared the 2018 $1 million Kavli Prize in nanoscience for his CRISPR work. And Feng Zhang of the Broad Institute is more widely cited than the above three, Pendlebury said, a marker of what colleagues think.

CRISPR citations built up more to Feng Zheng et al. than to Doudna and Charpentier, but I dont think that matters as much as judgments about priority claim, Pendlebury said. There are more than three to credit and I do think that is problematic. Bad feelings are not something the Nobel Assembly wants to generate, I am sure.

CRISPR will win, said CSHLs Sheltzer. Its a question of when, not if. Zhang/Doudna/Charpentier/Horvath/Barrangou shared the Gairdner. Pick 2 or 3 of them?

Go here to see the original:
Dust off the crystal ball: It's time for STAT's 2020 Nobel Prize predictions - STAT

Posted in California Stem Cells | Comments Off on Dust off the crystal ball: It’s time for STAT’s 2020 Nobel Prize predictions – STAT

Want to Know Where The Best Fall Colors Are in Your Area? Check Out This Interactive US Map – Good News Network

Posted: October 5, 2020 at 2:52 pm

Across the northern hemisphere, leaves are currently turning from deep summer green to the most brilliant shades of red and orange, yellow and gold.

Its quite the show, and for leaf peepers in the Lower 48, its possible to take a look at a virtual, interactive map to see just where the tree leaves are at their brilliant best.

At SmokyMountains.com, publicly accessible data such as National Oceanic and Atmospheric Administration precipitation forecasts, temperature forecasts, and average daylight exposure gets collated and synthesized in order to create a map that changes color according to where the most colorful scenes might be seen across the States.

Co-founder of the map, David Angotti, noted that its predictions arentquite perfect. It might show amazing fall colors happened in the middle of Arizona, but if there are no deciduous trees in that areaof course there wont be much of a show.

I wish I could make fall happen in South Florida or in the desert, Angotti told the Washington Post, but at the end of the day, the math is basically showing when the temperature and precipitation trendswouldcause peak fall to occur in each of these areas.

RELATED: Stunning Aerial Video of Icelands Green VolcanoCan Soothe Your Lockdown Stress

So just why do leaves change their color? According to SmokyMountains.com, As the fall days begin to get shorter and shorter, the production of chlorophyll slows to a halt, eventually giving way to the true color of the leaf.

When it gets cold, the trees then slowly close off the veins that carry water and nutrients to and from the leaves with a layer of new cells that form at the base of the leaf stem, protecting the limbs and body of the tree.

MORE: Americans Say COVID-19 Has Given Them a Newfound Appreciation of Nature

Once the process of new cell creation is complete, water and nutrients no longer flow to and from the leafthis enables the leaf to die and weaken at the stem, eventually falling gracefully to the ground.

Graceful is the word. We hope its beautiful where you are right now.

PASS This Story On To The Leaf Peepers In Your Life Via Social Media

Continue reading here:
Want to Know Where The Best Fall Colors Are in Your Area? Check Out This Interactive US Map - Good News Network

Posted in Arizona Stem Cells | Comments Off on Want to Know Where The Best Fall Colors Are in Your Area? Check Out This Interactive US Map – Good News Network

Page 880«..1020..879880881882..890900..»